1351534-07-0

Basic information

• Product Name: (2R)-[5-(bromomethyl)-2-chlorophenoxy]propanoic acid methyl ester
• CAS NO: 1351534-07-0
• Molecular Weight: 307.571
• Mol File: 1351534-07-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (2R)-[5-(bromomethyl)-2-chlorophenoxy]propanoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-[5-(bromomethyl)-2-chlorophenoxy]propanoic acid methyl ester(1351534-07-0)
• EPA Substance Registry System: (2R)-[5-(bromomethyl)-2-chlorophenoxy]propanoic acid methyl ester(1351534-07-0)

Safety Data

• Hazardous Substances Data: 1351534-07-0(Hazardous Substances Data)

Upstream product

• 615-74-7 2-chloro-5-methylphenol 
• 1351534-06-9 (2R)-(2-chloro-5-methylphenoxy)propanoic acid methyl ester 

Downstream Products

• 1351534-20-7 (2R)-2-[2-chloro-5-[[3-(5-chlorobenzisoxazol-3-yl)-2-oxo-6-trifluoromethylbenzimidazol-1-yl]methyl]phenoxy]propanoic acid 
• 1351534-21-8 (2R)-2-[2-chloro-5-[[3-(6-methoxybenzisoxazol-3-yl)-2-oxo-6-trifluoromethylbenzimidazol-1-yl]methyl]phenoxy]propanoic acid 
• 1351534-22-9 (2R)-2-[2-chloro-5-[[3-(6-methoxybenzisoxazol-3-yl)-2-oxo-6-trifluoromethoxybenzimidazol-1-yl]methyl]phenoxy]propanoic acid 
• 1351534-23-0 (2R)-2-[2-chloro-5-[[3-(6-methoxybenzisoxazol-3-yl)-2-oxo-5-trifluoromethylbenzimidazol-1-yl]methyl]phenoxy]propanoic acid 
• 1351534-16-1 (2R)-2-[2-chloro-5-[[3-(6-chlorobenzisoxazol-3-yl)-2-oxo-6-trifluoromethylbenzimidazol-1-yl]methyl]phenoxy]propanoic acid 
• 1351534-24-1 (2R)-2-[2-chloro-5-[[3-(6-methoxybenzisoxazol-3-yl)-2-oxo-5-trifluoromethoxybenzimidazol-1-yl]methyl]phenoxy]propanoic acid 
• 1351534-31-0 (2R)-2-[2-chloro-5-[[3-(6-methoxybenzisoxazol-3-yl)-2-oxo-benzimidazol-1-yl]methyl]phenoxy]propanoic acid 

Relevant articles and documents

N-BENZYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. Side effects such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, can be avoided in the mammal receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.